{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:43:35Z","timestamp":1760550215389},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,7,14]]},"abstract":" PURPOSE: To calculate radiation doses of rhenium-186 (186<\/jats:sup>Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief. We also wanted to determine whether technetium-99m (99m<\/jats:sup>Tc) methylene diphosphonate (MDP) concentrations predict radiation doses of 186<\/jats:sup>Re etidronate in painful lesions. <\/jats:p> MATERIALS AND METHODS: Forty-eight patients with breast and prostate cancer were evaluated. Patients received therapeutic doses of 186<\/jats:sup>Re etidronate. The area under the pain over time curve (AUPC) was measured for 8 weeks after treatment. Response was calculated as the percentage of change in AUPC. Quantitative bone SPECT (QBS)\u2013measured concentration of 186<\/jats:sup>Re etidronate was used for calculating radiation doses. Receiver operating characteristics curve analysis determined the radiation dose threshold that best separated responders from nonresponders. SPECT-measured concentration of 186<\/jats:sup>Re etidronate in the urinary bladder was correlated with its concentration in the voided urine. Concentration of 99m<\/jats:sup>Tc MDP was compared with radiation doses to painful metastases. <\/jats:p> RESULTS: The radiation dose threshold was 2.10 Gy. For a decrease of 50% in the AUPC, the positive predictive value (PPV) of this value was 75% and the negative predictive value (NPV) was 88%. For a decrease in pain of 33%, the PPV was 84% and the NPV was 81%. In prostate cancer patients only, the PPV was 81% and the NPV was 92%. The correlation between in vivo\/in vitro measured urine concentration was 0.90. The correlation between 99m<\/jats:sup>Tc MDP concentration and radiation doses of 186<\/jats:sup>Re etidronate was 0.92. <\/jats:p> CONCLUSION: QBS-measured radiation doses of 186<\/jats:sup>Re etidronate in painful metastases are a good predictor of pain relief. Bone SPECT using 99m<\/jats:sup>Tc MDP predicts radiation doses delivered by 186<\/jats:sup>Re etidronate. <\/jats:p>","DOI":"10.1200\/jco.2000.18.14.2747","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:50:00Z","timestamp":1487919000000},"page":"2747-2754","source":"Crossref","is-referenced-by-count":14,"title":["Quantitative Bone Single-Photon Emission Computed Tomography for Prediction of Pain Relief in Metastatic Bone Disease Treated With Rhenium-186 Etidronate"],"prefix":"10.1200","volume":"18","author":[{"given":"Ora","family":"Israel","sequence":"first","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohar","family":"Keidar","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rubinov","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Iosilevski","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Frenkel","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Kuten","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Betman","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald M.","family":"Kolodny","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Yarnitsky","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dov","family":"Front","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear MedicineOncology, and Neurology, Rambam Medical Center; Department of Oncology, Lady Davis Carmel Hospital; and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R2-0354","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(97)80046-3"},{"key":"R3-0354","doi-asserted-by":"publisher","DOI":"10.1007\/BF02261248"},{"key":"R4-0354","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.166.2.3122267"},{"key":"R5-0354","unstructured":"Maxon HR III, Schroder LE, Hertzberg VS, et al: Rhenium-186 (Sn) HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo. J Nucl Med 32:1877,1991-1881,"},{"key":"R6-0354","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050174"},{"key":"R7-0354","unstructured":"De Klerk JMH, Van Dijk A, Van het Schip AD, et al: Pharmacokinetics of rhenium-186 after administration of rhenium-186 HEDP to patients with bone metastases. J Nucl Med 33:646,1992-651,"},{"key":"R8-0354","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(05)80155-2"},{"key":"R9-0354","unstructured":"De Klerk JMH, Van het Schip AD, Zonnenberg BA, et al: Phase I study of rhenium-186 HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 37:244,1996-249,"},{"key":"R10-0354","unstructured":"Quirijnen JMSP, Han SH, Zonnenberg BA, et al: Efficacy of rhenium-186 etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 37:1511,1996-1515,"},{"key":"R11-0354","unstructured":"De Klerk JMH, Van het Schipp AD, Zonnenberg BA, et al: Evaluation of thrombocytopenia in patients treated with rhenium-186 HEDP: Guidelines for individual dosage recommendations. J Nucl Med 35:1423,1994-1428,"},{"key":"R12-0354","unstructured":"Han SH, Zonnenberg BA, De Klerk JMH, et al: Re-186 etidronate in breast cancer patients with metastatic bone pain. J Nucl Med 40:639,1999-642,"},{"key":"R13-0354","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(89)80034-0"},{"key":"R14-0354","unstructured":"Front D, Israel O, Jerushalmi J, et al: Quantitative bone scintigraphy (QBS) using SPECT. J Nucl Med 30:240,1989-245,"},{"key":"R15-0354","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.165.1.2442794"},{"key":"R16-0354","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.942"},{"key":"R17-0354","unstructured":"Israel O, Gorenberg M, Frenkel A, et al: Local and systemic effects of radiation on bone metabolism measured by quantitative SPECT. J Nucl Med 33:1774,1992-1782,"},{"key":"R18-0354","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.196.3.7644623"},{"key":"R19-0354","unstructured":"Loevinger R, Berman A: A schema for absorbed dose calculations for biologically distributed radionuclides: MIRD pamphlet no. 1. J Nucl Med 9:7,1968-14, (suppl 1)"},{"key":"R20-0354","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1926"},{"key":"R21-0354","unstructured":"Breen SL, Powe JE, Porter AT: Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 33:1316,1992-1323,"},{"key":"R22-0354","unstructured":"Giammarile F, Mognetti T, Blondet C, et al: Bone pain palliation with Sr-85 therapy. J Nucl Med 40:585,1999-590,"},{"key":"R23-0354","unstructured":"Blake GM, Zivanovic MA, Blaquiere RM, et al: Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases. J Nucl Med 29:549,1988-557,"},{"key":"R24-0354","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03300160027019"},{"key":"R25-0354","unstructured":"Hoskin PJ: Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv 7:69,1988-85,"},{"key":"R26-0354","unstructured":"Heggie JCP: Radiation absorbed dose calculations for samarium-153 EDTMP localized in bone. J Nucl Med 32:840,1991-844,"},{"key":"R27-0354","unstructured":"Samaratunga RC, Thomas SR, Hinnefeld JD, et al: A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186 (Sn)-HEDP. J Nucl Med 36:336,1995-350,"},{"key":"R28-0354","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197901000-00004"},{"key":"R29-0354","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00062-5"},{"key":"R30-0354","unstructured":"Silberstein EB: Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J Nucl Med 37:249,1996-251,"},{"key":"R31-0354","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y"},{"key":"R32-0354","unstructured":"Shapiro B: Optimization of radioiodine therapy of thyrotoxicosis: What have we learned after 50 years? J Nucl Med 34:1636,1993-1637,"},{"key":"R33-0354","doi-asserted-by":"crossref","unstructured":"Serafini AN, Houston SJ, Resche I, et al: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 4:1574,1998-1581,","DOI":"10.1200\/JCO.1998.16.4.1574"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.14.2747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:37:21Z","timestamp":1653514641000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.14.2747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7,14]]},"references-count":32,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2000,7,14]]}},"alternative-id":["10.1200\/JCO.2000.18.14.2747"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.14.2747","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7,14]]}}}